Teleflex (NYSE:TFX) Updates FY 2026 Earnings Guidance

Teleflex (NYSE:TFX) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 6.250-6.550 for the period, compared to the consensus EPS estimate of 15.180. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $3.7 billion.

Teleflex Price Performance

Shares of TFX stock opened at $121.95 on Friday. The firm has a market cap of $5.39 billion, a P/E ratio of -5.93, a P/E/G ratio of 1.55 and a beta of 0.92. The firm has a fifty day moving average of $111.34 and a two-hundred day moving average of $118.72. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.57 and a quick ratio of 1.53. Teleflex has a 1-year low of $100.18 and a 1-year high of $143.32.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.73 by ($1.80). The firm had revenue of $569.00 million for the quarter, compared to analyst estimates of $912.57 million. Teleflex had a negative net margin of 30.56% and a positive return on equity of 13.48%. The business’s revenue was down 28.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.89 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, research analysts anticipate that Teleflex will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Friday, March 6th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Friday, March 6th. This represents a $1.36 annualized dividend and a yield of 1.1%. Teleflex’s dividend payout ratio is presently -18.50%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Royal Bank Of Canada upped their price target on shares of Teleflex from $115.00 to $125.00 and gave the company a “sector perform” rating in a research report on Friday. Wall Street Zen lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Needham & Company LLC boosted their price target on shares of Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a report on Thursday. Finally, Truist Financial upped their price target on shares of Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research note on Thursday, December 18th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $140.71.

Key Headlines Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Wells Fargo raised its price target to $130 (from $116) and maintained an “equal weight” rating — a near-term bullish signal that can support buying interest. Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $125 (from $115) with a “sector perform” rating — another analyst lift that helps underpin the rally. Read More.
• Positive Sentiment: Teleflex’s board declared a quarterly cash dividend of $0.34 per share (record date March 6, payable March 31), which can attract income-seeking investors and provide support. Read More.
• Positive Sentiment: The company launched a multi‑year restructuring tied to planned divestitures — investors appear to view this as steps to simplify the portfolio, cut costs and potentially unlock value. Read More.
• Neutral Sentiment: Teleflex published its Q4 presentation and full-year results (material and earnings‑call transcripts are available) — useful for modeling but not a driver by itself. Read More.
• Negative Sentiment: Q4 results missed materially: EPS $1.93 vs. consensus ~$3.73 and revenue $569M vs. ~$912.6M — revenue fell ~28.5% year-over-year and margins contracted, a clear near-term negative for earnings momentum. Read More.
• Negative Sentiment: FY‑2026 guidance was significantly reduced: EPS guidance of $6.25–$6.55 and revenue guidance around $2.3B vs. street expectations materially higher (~$15 EPS and ~$3.7B revenue), which is a major downward re‑rating of near-term expectations. Read More.

Institutional Investors Weigh In On Teleflex

Hedge funds and other institutional investors have recently made changes to their positions in the business. UMB Bank n.a. raised its position in Teleflex by 57.1% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 113 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of Teleflex by 1.5% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company’s stock worth $1,056,000 after buying an additional 129 shares in the last quarter. Osaic Holdings Inc. lifted its position in shares of Teleflex by 17.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,247 shares of the medical technology company’s stock worth $148,000 after buying an additional 186 shares during the period. Vident Advisory LLC boosted its stake in Teleflex by 2.8% in the 4th quarter. Vident Advisory LLC now owns 6,992 shares of the medical technology company’s stock valued at $853,000 after buying an additional 188 shares in the last quarter. Finally, Empowered Funds LLC raised its stake in Teleflex by 15.8% during the first quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock worth $233,000 after acquiring an additional 230 shares in the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.